Expression of cytokeratin 20 in urinary cytology of patients with bladder carcinoma

BACKGROUND Of the 20 known cytokeratins, CK‐19 is expressed in normal urothelium, whereas the recently identified CK‐20 is expressed in urothelial carcinoma cells but not in normal urothelial cells. The aim of this study was to examine whether CK‐20 expression could serve as a noninvasive test in wh...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer 1998-01, Vol.82 (2), p.349-354
Hauptverfasser: Klein, Ami, Zemer, Ruth, Buchumensky, Victor, Klaper, Ronen, Nissenkorn, Israel
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 354
container_issue 2
container_start_page 349
container_title Cancer
container_volume 82
creator Klein, Ami
Zemer, Ruth
Buchumensky, Victor
Klaper, Ronen
Nissenkorn, Israel
description BACKGROUND Of the 20 known cytokeratins, CK‐19 is expressed in normal urothelium, whereas the recently identified CK‐20 is expressed in urothelial carcinoma cells but not in normal urothelial cells. The aim of this study was to examine whether CK‐20 expression could serve as a noninvasive test in which malignant urothelial cells in urine are detected and monitored. METHODS In the current study, the authors used reverse transcriptase‐polymerase chain reaction (RT‐PCR) methods to determine the expression of CK‐20 in cells separated from the urine of patients with bladder carcinoma. Cells were obtained from the urine of 87 patients divided into the following 2 groups: 1) 14 healthy volunteers without any known history of transitional cell carcinoma (TCC), and 2) 73 patients with hematuria suspected for TCC of the bladder. For control purposes, CK‐20 expression was examined in cells of 1) bladder carcinoma tumors of 5 patients, 2) blood of either patients with bladder carcinoma (n = 5) or healthy controls (n = 5), and 3) three different cell lines. RNA of the various cell pellets was extracted and RT‐PCR was performed with CK‐20 and CK‐19 primers (CK‐19 was used as a marker for normal epithelial cells). RESULTS CK‐20 amplification band (370 bp) was obtained with mRNA extracted from TCC cells of either bladder tumor or HT‐29 line (a CK‐20 colon carcinoma line). Sensitivity of the method was found to be 91%, whereas specificity was 67%. Among the 7 false‐positive cases, 3 showed atypia, 3 hyperplasia, and 1 metaplasia, and 2 underwent previously successful TCC tumor removals, suggesting that the CK‐20 test also responded to premalignant lesions. No false‐positive cases were found in the healthy control group. No other preparation, including blood of the patients of with TCC, showed the CK‐20 amplification band. CONCLUSIONS These results indicate that CK‐20 is a potential biomarker for noninvasive detection of bladder carcinoma by assaying uroepithelial cells from the voided urine specimen with RT‐PCR. Cancer 1998;82:320‐330. © 1998 American Cancer Society. Detection of CK‐20 gene expression by reverse transcriptase‐polymerase chain reaction in urinary cytology can serve as a noninvasive method for detecting bladder carcinoma.
doi_str_mv 10.1002/(SICI)1097-0142(19980115)82:2<355::AID-CNCR16>3.0.CO;2-Y
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79663100</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>79663100</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4796-35472a69d8b28ebca293ee19da757aa923d53fb57c75982bbe8f0b7e53cb8bc83</originalsourceid><addsrcrecordid>eNqFkF1v0zAYhS0EGt3gJyDlAqHtIsUfcW0XhDaFbVSaVomBtHHzynYcMKRJsVON_nscGnoD0m5s2ef4vMcPQqcETwnG9PXxzaJcnBCsRI5JQY-JUhITwk8kndO3jPP5_GzxPi-vy49k9o5N8bRcvqH53SM02T96jCYYY5nzgt0-RYcxfk9HQTk7QAeqKDhRbIJuzn-tg4vRd23W1Znd9t0PF3Tv24ziLK2b4Fsdtn-Upvu6HVzrpLu2j9m9779lptFV5UJmdbC-7Vb6GXpS6ya65-N-hD5fnH8qP-RXy8tFeXaV20KoWc54IaieqUoaKp2xmirmHFGVFlxorSirOKsNF1ZwJakxTtbYCMeZNdJYyY7Qq13uOnQ_Ny72sPLRuqbRres2EdKQGUs4k_F2Z7ShizG4GtbBr9KvgGAYeAMMvGFABwM6-MsbJAUKiTdA4g073sAAQ7lMwl2KfjF22JiVq_bBI-Ckvxx1Ha1u6qBb6-PeRglRlNNk-7Kz3fvGbf-p92C7_5Ybb9hv6z-pyQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79663100</pqid></control><display><type>article</type><title>Expression of cytokeratin 20 in urinary cytology of patients with bladder carcinoma</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Access via Wiley Online Library</source><source>Wiley Online Library (Open Access Collection)</source><source>Alma/SFX Local Collection</source><creator>Klein, Ami ; Zemer, Ruth ; Buchumensky, Victor ; Klaper, Ronen ; Nissenkorn, Israel</creator><creatorcontrib>Klein, Ami ; Zemer, Ruth ; Buchumensky, Victor ; Klaper, Ronen ; Nissenkorn, Israel</creatorcontrib><description>BACKGROUND Of the 20 known cytokeratins, CK‐19 is expressed in normal urothelium, whereas the recently identified CK‐20 is expressed in urothelial carcinoma cells but not in normal urothelial cells. The aim of this study was to examine whether CK‐20 expression could serve as a noninvasive test in which malignant urothelial cells in urine are detected and monitored. METHODS In the current study, the authors used reverse transcriptase‐polymerase chain reaction (RT‐PCR) methods to determine the expression of CK‐20 in cells separated from the urine of patients with bladder carcinoma. Cells were obtained from the urine of 87 patients divided into the following 2 groups: 1) 14 healthy volunteers without any known history of transitional cell carcinoma (TCC), and 2) 73 patients with hematuria suspected for TCC of the bladder. For control purposes, CK‐20 expression was examined in cells of 1) bladder carcinoma tumors of 5 patients, 2) blood of either patients with bladder carcinoma (n = 5) or healthy controls (n = 5), and 3) three different cell lines. RNA of the various cell pellets was extracted and RT‐PCR was performed with CK‐20 and CK‐19 primers (CK‐19 was used as a marker for normal epithelial cells). RESULTS CK‐20 amplification band (370 bp) was obtained with mRNA extracted from TCC cells of either bladder tumor or HT‐29 line (a CK‐20 colon carcinoma line). Sensitivity of the method was found to be 91%, whereas specificity was 67%. Among the 7 false‐positive cases, 3 showed atypia, 3 hyperplasia, and 1 metaplasia, and 2 underwent previously successful TCC tumor removals, suggesting that the CK‐20 test also responded to premalignant lesions. No false‐positive cases were found in the healthy control group. No other preparation, including blood of the patients of with TCC, showed the CK‐20 amplification band. CONCLUSIONS These results indicate that CK‐20 is a potential biomarker for noninvasive detection of bladder carcinoma by assaying uroepithelial cells from the voided urine specimen with RT‐PCR. Cancer 1998;82:320‐330. © 1998 American Cancer Society. Detection of CK‐20 gene expression by reverse transcriptase‐polymerase chain reaction in urinary cytology can serve as a noninvasive method for detecting bladder carcinoma.</description><identifier>ISSN: 0008-543X</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/(SICI)1097-0142(19980115)82:2&lt;355::AID-CNCR16&gt;3.0.CO;2-Y</identifier><identifier>PMID: 9445193</identifier><identifier>CODEN: CANCAR</identifier><language>eng</language><publisher>New York: John Wiley &amp; Sons, Inc</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Biological and medical sciences ; Biomarkers, Tumor - analysis ; Biomarkers, Tumor - blood ; Biomarkers, Tumor - genetics ; Biomarkers, Tumor - urine ; Carcinoma, Transitional Cell - blood ; Carcinoma, Transitional Cell - pathology ; Carcinoma, Transitional Cell - urine ; False Positive Reactions ; Female ; Gene Expression Regulation, Neoplastic ; Hematuria - pathology ; Hematuria - urine ; HT29 Cells - pathology ; Humans ; Hyperplasia ; Investigative techniques, diagnostic techniques (general aspects) ; Keratins - analysis ; Keratins - blood ; Keratins - genetics ; Keratins - urine ; Male ; Medical sciences ; Metaplasia ; Middle Aged ; Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques ; Polymerase Chain Reaction ; Precancerous Conditions - blood ; Precancerous Conditions - pathology ; Precancerous Conditions - urine ; RNA, Messenger - analysis ; RNA, Messenger - genetics ; Sensitivity and Specificity ; Transcription, Genetic ; Tumor Cells, Cultured ; Urinary Bladder ; Urinary Bladder - pathology ; Urinary Bladder Neoplasms - blood ; Urinary Bladder Neoplasms - pathology ; Urinary Bladder Neoplasms - urine ; Urinary system ; Urothelium - pathology</subject><ispartof>Cancer, 1998-01, Vol.82 (2), p.349-354</ispartof><rights>Copyright © 1998 American Cancer Society</rights><rights>1998 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c4796-35472a69d8b28ebca293ee19da757aa923d53fb57c75982bbe8f0b7e53cb8bc83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2F%28SICI%291097-0142%2819980115%2982%3A2%3C355%3A%3AAID-CNCR16%3E3.0.CO%3B2-Y$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2F%28SICI%291097-0142%2819980115%2982%3A2%3C355%3A%3AAID-CNCR16%3E3.0.CO%3B2-Y$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,781,785,1418,1434,27929,27930,45579,45580,46414,46838</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=2119252$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9445193$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Klein, Ami</creatorcontrib><creatorcontrib>Zemer, Ruth</creatorcontrib><creatorcontrib>Buchumensky, Victor</creatorcontrib><creatorcontrib>Klaper, Ronen</creatorcontrib><creatorcontrib>Nissenkorn, Israel</creatorcontrib><title>Expression of cytokeratin 20 in urinary cytology of patients with bladder carcinoma</title><title>Cancer</title><addtitle>Cancer</addtitle><description>BACKGROUND Of the 20 known cytokeratins, CK‐19 is expressed in normal urothelium, whereas the recently identified CK‐20 is expressed in urothelial carcinoma cells but not in normal urothelial cells. The aim of this study was to examine whether CK‐20 expression could serve as a noninvasive test in which malignant urothelial cells in urine are detected and monitored. METHODS In the current study, the authors used reverse transcriptase‐polymerase chain reaction (RT‐PCR) methods to determine the expression of CK‐20 in cells separated from the urine of patients with bladder carcinoma. Cells were obtained from the urine of 87 patients divided into the following 2 groups: 1) 14 healthy volunteers without any known history of transitional cell carcinoma (TCC), and 2) 73 patients with hematuria suspected for TCC of the bladder. For control purposes, CK‐20 expression was examined in cells of 1) bladder carcinoma tumors of 5 patients, 2) blood of either patients with bladder carcinoma (n = 5) or healthy controls (n = 5), and 3) three different cell lines. RNA of the various cell pellets was extracted and RT‐PCR was performed with CK‐20 and CK‐19 primers (CK‐19 was used as a marker for normal epithelial cells). RESULTS CK‐20 amplification band (370 bp) was obtained with mRNA extracted from TCC cells of either bladder tumor or HT‐29 line (a CK‐20 colon carcinoma line). Sensitivity of the method was found to be 91%, whereas specificity was 67%. Among the 7 false‐positive cases, 3 showed atypia, 3 hyperplasia, and 1 metaplasia, and 2 underwent previously successful TCC tumor removals, suggesting that the CK‐20 test also responded to premalignant lesions. No false‐positive cases were found in the healthy control group. No other preparation, including blood of the patients of with TCC, showed the CK‐20 amplification band. CONCLUSIONS These results indicate that CK‐20 is a potential biomarker for noninvasive detection of bladder carcinoma by assaying uroepithelial cells from the voided urine specimen with RT‐PCR. Cancer 1998;82:320‐330. © 1998 American Cancer Society. Detection of CK‐20 gene expression by reverse transcriptase‐polymerase chain reaction in urinary cytology can serve as a noninvasive method for detecting bladder carcinoma.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - analysis</subject><subject>Biomarkers, Tumor - blood</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Biomarkers, Tumor - urine</subject><subject>Carcinoma, Transitional Cell - blood</subject><subject>Carcinoma, Transitional Cell - pathology</subject><subject>Carcinoma, Transitional Cell - urine</subject><subject>False Positive Reactions</subject><subject>Female</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Hematuria - pathology</subject><subject>Hematuria - urine</subject><subject>HT29 Cells - pathology</subject><subject>Humans</subject><subject>Hyperplasia</subject><subject>Investigative techniques, diagnostic techniques (general aspects)</subject><subject>Keratins - analysis</subject><subject>Keratins - blood</subject><subject>Keratins - genetics</subject><subject>Keratins - urine</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Metaplasia</subject><subject>Middle Aged</subject><subject>Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques</subject><subject>Polymerase Chain Reaction</subject><subject>Precancerous Conditions - blood</subject><subject>Precancerous Conditions - pathology</subject><subject>Precancerous Conditions - urine</subject><subject>RNA, Messenger - analysis</subject><subject>RNA, Messenger - genetics</subject><subject>Sensitivity and Specificity</subject><subject>Transcription, Genetic</subject><subject>Tumor Cells, Cultured</subject><subject>Urinary Bladder</subject><subject>Urinary Bladder - pathology</subject><subject>Urinary Bladder Neoplasms - blood</subject><subject>Urinary Bladder Neoplasms - pathology</subject><subject>Urinary Bladder Neoplasms - urine</subject><subject>Urinary system</subject><subject>Urothelium - pathology</subject><issn>0008-543X</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkF1v0zAYhS0EGt3gJyDlAqHtIsUfcW0XhDaFbVSaVomBtHHzynYcMKRJsVON_nscGnoD0m5s2ef4vMcPQqcETwnG9PXxzaJcnBCsRI5JQY-JUhITwk8kndO3jPP5_GzxPi-vy49k9o5N8bRcvqH53SM02T96jCYYY5nzgt0-RYcxfk9HQTk7QAeqKDhRbIJuzn-tg4vRd23W1Znd9t0PF3Tv24ziLK2b4Fsdtn-Upvu6HVzrpLu2j9m9779lptFV5UJmdbC-7Vb6GXpS6ya65-N-hD5fnH8qP-RXy8tFeXaV20KoWc54IaieqUoaKp2xmirmHFGVFlxorSirOKsNF1ZwJakxTtbYCMeZNdJYyY7Qq13uOnQ_Ny72sPLRuqbRres2EdKQGUs4k_F2Z7ShizG4GtbBr9KvgGAYeAMMvGFABwM6-MsbJAUKiTdA4g073sAAQ7lMwl2KfjF22JiVq_bBI-Ckvxx1Ha1u6qBb6-PeRglRlNNk-7Kz3fvGbf-p92C7_5Ybb9hv6z-pyQ</recordid><startdate>19980115</startdate><enddate>19980115</enddate><creator>Klein, Ami</creator><creator>Zemer, Ruth</creator><creator>Buchumensky, Victor</creator><creator>Klaper, Ronen</creator><creator>Nissenkorn, Israel</creator><general>John Wiley &amp; Sons, Inc</general><general>Wiley-Liss</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19980115</creationdate><title>Expression of cytokeratin 20 in urinary cytology of patients with bladder carcinoma</title><author>Klein, Ami ; Zemer, Ruth ; Buchumensky, Victor ; Klaper, Ronen ; Nissenkorn, Israel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4796-35472a69d8b28ebca293ee19da757aa923d53fb57c75982bbe8f0b7e53cb8bc83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - analysis</topic><topic>Biomarkers, Tumor - blood</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Biomarkers, Tumor - urine</topic><topic>Carcinoma, Transitional Cell - blood</topic><topic>Carcinoma, Transitional Cell - pathology</topic><topic>Carcinoma, Transitional Cell - urine</topic><topic>False Positive Reactions</topic><topic>Female</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Hematuria - pathology</topic><topic>Hematuria - urine</topic><topic>HT29 Cells - pathology</topic><topic>Humans</topic><topic>Hyperplasia</topic><topic>Investigative techniques, diagnostic techniques (general aspects)</topic><topic>Keratins - analysis</topic><topic>Keratins - blood</topic><topic>Keratins - genetics</topic><topic>Keratins - urine</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Metaplasia</topic><topic>Middle Aged</topic><topic>Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques</topic><topic>Polymerase Chain Reaction</topic><topic>Precancerous Conditions - blood</topic><topic>Precancerous Conditions - pathology</topic><topic>Precancerous Conditions - urine</topic><topic>RNA, Messenger - analysis</topic><topic>RNA, Messenger - genetics</topic><topic>Sensitivity and Specificity</topic><topic>Transcription, Genetic</topic><topic>Tumor Cells, Cultured</topic><topic>Urinary Bladder</topic><topic>Urinary Bladder - pathology</topic><topic>Urinary Bladder Neoplasms - blood</topic><topic>Urinary Bladder Neoplasms - pathology</topic><topic>Urinary Bladder Neoplasms - urine</topic><topic>Urinary system</topic><topic>Urothelium - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Klein, Ami</creatorcontrib><creatorcontrib>Zemer, Ruth</creatorcontrib><creatorcontrib>Buchumensky, Victor</creatorcontrib><creatorcontrib>Klaper, Ronen</creatorcontrib><creatorcontrib>Nissenkorn, Israel</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Klein, Ami</au><au>Zemer, Ruth</au><au>Buchumensky, Victor</au><au>Klaper, Ronen</au><au>Nissenkorn, Israel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Expression of cytokeratin 20 in urinary cytology of patients with bladder carcinoma</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>1998-01-15</date><risdate>1998</risdate><volume>82</volume><issue>2</issue><spage>349</spage><epage>354</epage><pages>349-354</pages><issn>0008-543X</issn><eissn>1097-0142</eissn><coden>CANCAR</coden><abstract>BACKGROUND Of the 20 known cytokeratins, CK‐19 is expressed in normal urothelium, whereas the recently identified CK‐20 is expressed in urothelial carcinoma cells but not in normal urothelial cells. The aim of this study was to examine whether CK‐20 expression could serve as a noninvasive test in which malignant urothelial cells in urine are detected and monitored. METHODS In the current study, the authors used reverse transcriptase‐polymerase chain reaction (RT‐PCR) methods to determine the expression of CK‐20 in cells separated from the urine of patients with bladder carcinoma. Cells were obtained from the urine of 87 patients divided into the following 2 groups: 1) 14 healthy volunteers without any known history of transitional cell carcinoma (TCC), and 2) 73 patients with hematuria suspected for TCC of the bladder. For control purposes, CK‐20 expression was examined in cells of 1) bladder carcinoma tumors of 5 patients, 2) blood of either patients with bladder carcinoma (n = 5) or healthy controls (n = 5), and 3) three different cell lines. RNA of the various cell pellets was extracted and RT‐PCR was performed with CK‐20 and CK‐19 primers (CK‐19 was used as a marker for normal epithelial cells). RESULTS CK‐20 amplification band (370 bp) was obtained with mRNA extracted from TCC cells of either bladder tumor or HT‐29 line (a CK‐20 colon carcinoma line). Sensitivity of the method was found to be 91%, whereas specificity was 67%. Among the 7 false‐positive cases, 3 showed atypia, 3 hyperplasia, and 1 metaplasia, and 2 underwent previously successful TCC tumor removals, suggesting that the CK‐20 test also responded to premalignant lesions. No false‐positive cases were found in the healthy control group. No other preparation, including blood of the patients of with TCC, showed the CK‐20 amplification band. CONCLUSIONS These results indicate that CK‐20 is a potential biomarker for noninvasive detection of bladder carcinoma by assaying uroepithelial cells from the voided urine specimen with RT‐PCR. Cancer 1998;82:320‐330. © 1998 American Cancer Society. Detection of CK‐20 gene expression by reverse transcriptase‐polymerase chain reaction in urinary cytology can serve as a noninvasive method for detecting bladder carcinoma.</abstract><cop>New York</cop><pub>John Wiley &amp; Sons, Inc</pub><pmid>9445193</pmid><doi>10.1002/(SICI)1097-0142(19980115)82:2&lt;355::AID-CNCR16&gt;3.0.CO;2-Y</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0008-543X
ispartof Cancer, 1998-01, Vol.82 (2), p.349-354
issn 0008-543X
1097-0142
language eng
recordid cdi_proquest_miscellaneous_79663100
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Access via Wiley Online Library; Wiley Online Library (Open Access Collection); Alma/SFX Local Collection
subjects Adult
Aged
Aged, 80 and over
Biological and medical sciences
Biomarkers, Tumor - analysis
Biomarkers, Tumor - blood
Biomarkers, Tumor - genetics
Biomarkers, Tumor - urine
Carcinoma, Transitional Cell - blood
Carcinoma, Transitional Cell - pathology
Carcinoma, Transitional Cell - urine
False Positive Reactions
Female
Gene Expression Regulation, Neoplastic
Hematuria - pathology
Hematuria - urine
HT29 Cells - pathology
Humans
Hyperplasia
Investigative techniques, diagnostic techniques (general aspects)
Keratins - analysis
Keratins - blood
Keratins - genetics
Keratins - urine
Male
Medical sciences
Metaplasia
Middle Aged
Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques
Polymerase Chain Reaction
Precancerous Conditions - blood
Precancerous Conditions - pathology
Precancerous Conditions - urine
RNA, Messenger - analysis
RNA, Messenger - genetics
Sensitivity and Specificity
Transcription, Genetic
Tumor Cells, Cultured
Urinary Bladder
Urinary Bladder - pathology
Urinary Bladder Neoplasms - blood
Urinary Bladder Neoplasms - pathology
Urinary Bladder Neoplasms - urine
Urinary system
Urothelium - pathology
title Expression of cytokeratin 20 in urinary cytology of patients with bladder carcinoma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-12T20%3A57%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Expression%20of%20cytokeratin%2020%20in%20urinary%20cytology%20of%20patients%20with%20bladder%20carcinoma&rft.jtitle=Cancer&rft.au=Klein,%20Ami&rft.date=1998-01-15&rft.volume=82&rft.issue=2&rft.spage=349&rft.epage=354&rft.pages=349-354&rft.issn=0008-543X&rft.eissn=1097-0142&rft.coden=CANCAR&rft_id=info:doi/10.1002/(SICI)1097-0142(19980115)82:2%3C355::AID-CNCR16%3E3.0.CO;2-Y&rft_dat=%3Cproquest_cross%3E79663100%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=79663100&rft_id=info:pmid/9445193&rfr_iscdi=true